Literature DB >> 24770979

[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

G Klose1, F U Beil, H Dieplinger, A von Eckardstein, B Föger, I Gouni-Berthold, W Koenig, G M Kostner, U Landmesser, U Laufs, F Leistikow, W März, M Merkel, D Müller-Wieland, G Noll, K G Parhofer, B Paulweber, W Riesen, J R Schaefer, E Steinhagen-Thiessen, A Steinmetz, H Toplak, C Wanner, E Windler.   

Abstract

Guidelines for the reduction of cholesterol to prevent atherosclerotic vascular events were recently released by the American Heart Association and the American College of Cardiology. The authors claim to refer entirely to evidence from randomized controlled trials, thereby confining their guidelines to statins as the primary therapeutic option. The guidelines derived from these trials do not specify treatment goals, but refer to the percentage of cholesterol reduction by statin medication with low, moderate, and high intensity. However, these targets are just as little tested in randomized trials as are the cholesterol goals derived from clinical experience. The same applies to the guidelines of the four patient groups which are defined by vascular risk. No major statin trial has included patients on the basis of their global risk; thus the allocation criteria are also arbitrarily chosen. These would actually lead to a significant increase in the number of patients to be treated with high or maximum dosages of statins. Also, adhering to dosage regulations instead of cholesterol goals contradicts the principles of individualized patient care. The option of the new risk score to calculate lifetime risk up to the age of 80 years in addition to the 10-year risk can be appreciated. Unfortunately it is not considered in the therapeutic recommendations provided, despite evidence from population and genetic studies showing that even a moderate lifetime reduction of low-density lipoprotein (LDL) cholesterol or non-HDL cholesterol has a much stronger effect than an aggressive treatment at an advanced age. In respect to secondary prevention, the new American guidelines broadly match the European guidelines. Thus, the involved societies from Germany, Austria and Switzerland recommend continuing according to established standards, such as the EAS/ESC guidelines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24770979     DOI: 10.1007/s00108-014-3492-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Nutrition is a powerful independent risk factor for coronary heart disease in women--The CORA study: a population-based case-control study.

Authors:  B-C Zyriax; H Boeing; E Windler
Journal:  Eur J Clin Nutr       Date:  2005-10       Impact factor: 4.016

3.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

Review 4.  Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.

Authors:  Brian A Ference; Wonsuk Yoo; Issa Alesh; Nitin Mahajan; Karolina K Mirowska; Abhishek Mewada; Joel Kahn; Luis Afonso; Kim Allan Williams; John M Flack
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

5.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

6.  Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.

Authors:  Winfried März; Hubert Scharnagl; Karl Winkler; Andreas Tiran; Markus Nauck; Bernhard O Boehm; Bernhard R Winkelmann
Journal:  Circulation       Date:  2004-10-25       Impact factor: 29.690

7.  Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

Authors:  Marianne K DeGorter; Rommel G Tirona; Ute I Schwarz; Yun-Hee Choi; George K Dresser; Neville Suskin; Kathryn Myers; GuangYong Zou; Otito Iwuchukwu; Wei-Qi Wei; Russell A Wilke; Robert A Hegele; Richard B Kim
Journal:  Circ Cardiovasc Genet       Date:  2013-07-22

8.  Lifetime risk and years lived free of total cardiovascular disease.

Authors:  John T Wilkins; Hongyan Ning; Jarett Berry; Lihui Zhao; Alan R Dyer; Donald M Lloyd-Jones
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.